Outcome of Board meeting held on August 7, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eyantra Ventures' board approved standalone and consolidated unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue surged to ₹1,422.11 lakhs from ₹495.38 lakhs in Q1 FY25, a jump of about 187%, driven by stronger merchandise sales and IT services. However, standalone net profit fell sharply to ₹5.58 lakhs from ₹81.19 lakhs due to higher employee costs and other expenses. On a consolidated basis, revenue jumped to ₹1,956.41 lakhs but the company slipped into a net loss of ₹342.62 lakhs, largely because it began consolidating Neuro and Spine Associates (acquired control in April 2025), which itself posted a loss of ₹336.54 lakhs. The board also approved a new ESOP scheme for up to 2 lakh options and appointed Vivek Surana & Associates as Secretarial Auditor for five years. The 40th AGM is scheduled for September 30, 2025.
Strong top-line growth is positive, but profitability has deteriorated significantly — consolidated EPS turned negative at ₹(8.60) versus ₹4.49 a year ago. Investors should watch whether the newly consolidated healthcare subsidiary can turn profitable, as it is currently dragging down group earnings. The ESOP scheme may lead to mild future dilution if exercised.